Tehrani Shabnam, Khabiri Neda, Moradi Hamideh, Mosavat Mina Sadat, Khabiri Seyyed Saeed
Labbafinejad Clinical Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Infectious Diseases and Tropical Medicine Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Clin Nutr ESPEN. 2021 Apr;42:313-317. doi: 10.1016/j.clnesp.2021.01.014. Epub 2021 Jan 26.
Novel Coronavirus (COVID-19) first appeared in China in late 2019 which was rapidly spread worldwide. As the COVID-19 pandemic continues to spread, it is crucial to determine the prognostic factors contributing to the development of severe disease and higher mortality. Herein we aimed to evaluate the correlation between the severity and prognosis of patients with COVID 19 with serum 25(OH)D levels.
This descriptive retrospective study was performed from March to April 2020 at a referral center for patients with COVID-19, Tehran, Iran. The data collection was performed by a checklist consisting of the demographic features and laboratory assessments consisted of serum 25(OH)D were evaluated and recorded. And investigate the relationship between serum 25(OH)D and clinical outcomes of patients.
205 patients with a mean age of 59.71 years were enrolled. Our findings did not reveal a significant difference in mean levels of vitamin between improved (34.09) and deceased patients (34.54). However, in patients with severe disease, there was a considerable difference in levels of vitamin D in improved and deceased patients (P.value: 0.021). According to our results, the mortality rate was slightly higher in men (odds ratio:2.2). Furthermore, the mean age (64.20 vs. 58.51) and the presence of at least two comorbidities (odds ratio: 2.40) were significantly higher in deceased patients.
In this study, we did not reveal a statistical difference in mean levels of vitamin D and the outcome of patients with COVID-19. We concluded that in patients with severe disease, vitamin D deficiency could affect the course of the disease and mortality, especially in comorbidity and older people.
新型冠状病毒(COVID-19)于2019年末首次在中国出现,并迅速在全球传播。随着COVID-19大流行的持续蔓延,确定导致严重疾病和更高死亡率的预后因素至关重要。在此,我们旨在评估COVID-19患者的严重程度与预后与血清25(OH)D水平之间的相关性。
本描述性回顾性研究于2020年3月至4月在伊朗德黑兰一家COVID-19患者转诊中心进行。通过一份包含人口统计学特征的清单进行数据收集,并对包括血清25(OH)D在内的实验室评估进行评估和记录。并研究血清25(OH)D与患者临床结局之间的关系。
共纳入205例平均年龄为59.71岁的患者。我们的研究结果显示,病情改善患者(34.09)和死亡患者(34.54)的维生素平均水平无显著差异。然而,在重症患者中,病情改善患者和死亡患者的维生素D水平存在显著差异(P值:0.021)。根据我们的结果,男性的死亡率略高(比值比:2.2)。此外,死亡患者的平均年龄(64.20对58.51)和至少存在两种合并症的比例(比值比:2.40)显著更高。
在本研究中,我们未发现COVID-19患者的维生素D平均水平与结局之间存在统计学差异。我们得出结论,在重症患者中,维生素D缺乏可能会影响疾病进程和死亡率,尤其是在合并症患者和老年人中。